Literature DB >> 26082812

Assessment of Therapy Response by (18)F-FDG PET/CT for a Patient with Cutaneous and Subcutaneous Mycobacterium Infection and Coexisting Lymphoma.

Yang Lu1.   

Abstract

Entities:  

Year:  2014        PMID： 26082812      PMCID： PMC4463870          DOI： 10.1007/s13139-014-0312-2

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


× No keyword cloud information.
  7 in total

Review 1.  Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders.

Authors:  Hongming Zhuang; Jian Q Yu; Abass Alavi
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

2.  Disseminated nontuberculous mycobacterial infection mimic metastases on PET/CT scan.

Authors:  Kuan-Hsiu Lin; Jao-Hsien Wang; Nan-Jing Peng
Journal:  Clin Nucl Med       Date:  2008-04       Impact factor: 7.794

3.  Disseminated tuberculosis infection: a 'super' 18F-FDG PET/CT appearance.

Authors:  Abdul Jalil Nordin; Claudio Rossetti; Noraini Abdul Rahim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-19       Impact factor: 9.236

4.  18F-FDG imaging of a rare cutaneous infection by Mycobacterium avium complex.

Authors:  Zhemin Huang; Chun Qiu; Yihui Guan
Journal:  Clin Nucl Med       Date:  2014-03       Impact factor: 7.794

5.  Atypical mycobacteriosis caused by Mycobacterium haemophilum in an immunocompromised patient: diagnosis by (18)F-FDG PET/CT.

Authors:  Silvia Münster; Jozef Zustin; Thorsten Derlin
Journal:  Clin Nucl Med       Date:  2013-04       Impact factor: 7.794

6.  Systemic disseminated tuberculosis mimicking malignancy on F-18 FDG PET-CT.

Authors:  Ya-Jun Li; Yue Zhang; Shuo Gao; Ren-Ju Bai
Journal:  Clin Nucl Med       Date:  2008-01       Impact factor: 7.794

7.  Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT.

Authors:  Chandan Jyoti Das; Rakesh Kumar; Vijay Babu Balakrishnan; Madhavi Chawla; Arun Malhotra
Journal:  Clin Nucl Med       Date:  2008-05       Impact factor: 7.794
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.